Clinical Trial Update: Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases [Phase 2]

View source ↗

Summary

Phase II trial assessing Dato-DXd in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer with Brain Metastases
• Triple-negative Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: Medical University of Vienna | Conditions: Breast Cancer Stage IV | Phase 2 | Status: RECRUITING